Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAL 1000

Next Previous
X
Search
Drug Profile

VAL 1000

Alternative Names: VAL-1000

Latest Information Update: 11 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Senz Oncology
  • Developer Allyence Research; Senz Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 05 Feb 2020 Senz Oncology discontinued the phase-I/II clinical trials in Acute myeloid leukaemia, myelodysplastic syndromes, precursor cell lymphoblastic leukaemia lymphoma in Australia (PO) (ACTRN12612000970842)
  • 27 Aug 2015 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia, Acute myeloid leukaemia and Myelodysplastic syndromes in Australia (PO)
  • 22 Aug 2012 Clinical trials in Leukaemia in Australia (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top